"Pichia continues to grow in use and success in many markets. We are pleased to work with Integrated Genomics to help increase yield and activity of difficult to express proteins,” said Dr. Robert J. Molinari, CEO of CODA.
“This relationship exemplifies our continued expansion and success in solving protein expression bottlenecks,” Dr. Molinari continued.
"This combination of our proprietary Pichia sequence and metabolic reconstruction with CODA's unique expression optimization technology provides a tremendous opportunity for scientists optimizing protein expression in Pichia," added Dr. John Elling, President of Integrated Genomics.
CODA's proprietary protein Translation Engineering technologies are designed to address protein expression, solubility and activity challenges in rational design steps at all stages of pharmaceutical development.
This utilization of synthetic biology can change the competitive landscape of many businesses which rely on successful protein production.
Integrated Genomics can provide the genomic sequence of Pichia and other cell lines which are crucial for successful protein production.
The sequence, assembly and detailed annotation provided by Integrated Genomics will allow CODA to provide enhanced genes for protein expression without amino acid changes in proteins of interest.